SGRY250117P15000
- 0.00
- 0.000.00%
Surgery Partners Newsroom
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $28
U.S. Healthcare Spending Climbs 7.5% in 2023
Investors in Surgery Partners (NASDAQ:SGRY) Have Unfortunately Lost 53% Over the Last Three Years
Worst Performing Stocks for Tax Loss Selling – Wolfe
BofA Securities Initiates Surgery Partners(SGRY.US) With Buy Rating, Announces Target Price $30
JPMorgan Adjusts Surgery Partners Price Target to $28 From $38, Maintains Neutral Rating
Surgery Partners, Inc. (NASDAQ:SGRY) Is Expected To Breakeven In The Near Future
Surgery Partners Is Maintained at Outperform by RBC Capital
RBC Capital Maintains Surgery Partners(SGRY.US) With Buy Rating, Cuts Target Price to $35
Express News | Surgery Partners Inc : RBC Cuts Target Price to $35 From $49
Macquarie Maintains Surgery Partners(SGRY.US) With Buy Rating
Overreaction to Selloff: Surgery Partners' Undervalued Opportunity Amidst Strong Fundamentals
TD Cowen Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $32
Jefferies Maintains Surgery Partners(SGRY.US) With Buy Rating, Maintains Target Price $40
A Quick Look at Today's Ratings for Surgery Partners(SGRY.US), With a Forecast Between $31 to $50
Surgery Partners Third Quarter 2024 Earnings: EPS Misses Expectations
Surgery Partners Analyst Ratings
Surgery Partners Down Over 11%, on Pace for Largest Percent Decrease Since May 2022 -- Data Talk
Macquarie Adjusts Surgery Partners Price Target to $34 From $35, Maintains Outperform Rating
Mizuho Securities Maintains Surgery Partners(SGRY.US) With Buy Rating